Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases

Jakob Reiser, Xian Yang Zhang, Charles S. Hemenway, Debasis Mondal, Leena Pradhan, Vincent F. La Russa

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

The intriguing biology of stem cells and their vast clinical potential is emerging rapidly for gene therapy. Bone marrow stem cells, including the pluripotent haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and possibly the multipotent adherent progenitor cells (MAPCs), are being considered as potential targets for cell and gene therapy-based approaches against a variety of different diseases. The MSCs from bone marrow are a promising target population as they are capable of differentiating along multiple lineages and, at least in vitro, have significant expansion capability. The apparently high self-renewal potential makes them strong candidates for delivering genes and restoring organ systems function. However, the high proliferative potential of MSCs, now presumed to be self-renewal, may be more apparent than real. Although expanded MSCs have great proliferation and differentiation potential in vitro, there are limitations with the biology of these cells in vivo. So far, expanded MSCs have failed to induce durable therapeutic effects expected from a true self-renewing stem cell population. The loss of in vivo self-renewal may be due to the extensive expansion of MSCs in existing in vitro expansion systems, suggesting that the original stem cell population and/or properties may no longer exist. Rather, the expanded population may indeed be heterogeneous and represents several generations of different types of mesenchymal cell progeny that have retained a limited proliferation potential and responsiveness for terminal differentiation and maturation along mesenchymal and non-mesenchymal lineages. Novel technology that allows MSCs to maintain their stem cell function in vivo is critical for distinguishing the elusive stem cell from its progenitor cell populations. The ultimate dream is to use MSCs in various forms of cellular therapies, as well as genetic tools that can be used to better understand the mechanisms leading to repair and regeneration of damaged or diseased tissues and organs.

Original languageEnglish
Pages (from-to)1571-1584
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume5
Issue number12
DOIs
StatePublished - Dec 1 2005

Fingerprint

Gene therapy
Stem cells
Mesenchymal Stromal Cells
Genetic Therapy
Stem Cells
Population
Pluripotent Stem Cells
Health Services Needs and Demand
Therapeutic Uses
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Bone Marrow Cells
Cell Biology
Bone
Regeneration
Bone Marrow
Technology

Keywords

  • Gene Therapy
  • Mesenchymal stem cells
  • Vectors

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. / Reiser, Jakob; Zhang, Xian Yang; Hemenway, Charles S.; Mondal, Debasis; Pradhan, Leena; La Russa, Vincent F.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 12, 01.12.2005, p. 1571-1584.

Research output: Contribution to journalArticle

Reiser, Jakob ; Zhang, Xian Yang ; Hemenway, Charles S. ; Mondal, Debasis ; Pradhan, Leena ; La Russa, Vincent F. / Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. In: Expert Opinion on Biological Therapy. 2005 ; Vol. 5, No. 12. pp. 1571-1584.
@article{68498e03e15a458e9f40e4220a79b196,
title = "Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases",
abstract = "The intriguing biology of stem cells and their vast clinical potential is emerging rapidly for gene therapy. Bone marrow stem cells, including the pluripotent haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and possibly the multipotent adherent progenitor cells (MAPCs), are being considered as potential targets for cell and gene therapy-based approaches against a variety of different diseases. The MSCs from bone marrow are a promising target population as they are capable of differentiating along multiple lineages and, at least in vitro, have significant expansion capability. The apparently high self-renewal potential makes them strong candidates for delivering genes and restoring organ systems function. However, the high proliferative potential of MSCs, now presumed to be self-renewal, may be more apparent than real. Although expanded MSCs have great proliferation and differentiation potential in vitro, there are limitations with the biology of these cells in vivo. So far, expanded MSCs have failed to induce durable therapeutic effects expected from a true self-renewing stem cell population. The loss of in vivo self-renewal may be due to the extensive expansion of MSCs in existing in vitro expansion systems, suggesting that the original stem cell population and/or properties may no longer exist. Rather, the expanded population may indeed be heterogeneous and represents several generations of different types of mesenchymal cell progeny that have retained a limited proliferation potential and responsiveness for terminal differentiation and maturation along mesenchymal and non-mesenchymal lineages. Novel technology that allows MSCs to maintain their stem cell function in vivo is critical for distinguishing the elusive stem cell from its progenitor cell populations. The ultimate dream is to use MSCs in various forms of cellular therapies, as well as genetic tools that can be used to better understand the mechanisms leading to repair and regeneration of damaged or diseased tissues and organs.",
keywords = "Gene Therapy, Mesenchymal stem cells, Vectors",
author = "Jakob Reiser and Zhang, {Xian Yang} and Hemenway, {Charles S.} and Debasis Mondal and Leena Pradhan and {La Russa}, {Vincent F.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1517/14712598.5.12.1571",
language = "English",
volume = "5",
pages = "1571--1584",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases

AU - Reiser, Jakob

AU - Zhang, Xian Yang

AU - Hemenway, Charles S.

AU - Mondal, Debasis

AU - Pradhan, Leena

AU - La Russa, Vincent F.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The intriguing biology of stem cells and their vast clinical potential is emerging rapidly for gene therapy. Bone marrow stem cells, including the pluripotent haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and possibly the multipotent adherent progenitor cells (MAPCs), are being considered as potential targets for cell and gene therapy-based approaches against a variety of different diseases. The MSCs from bone marrow are a promising target population as they are capable of differentiating along multiple lineages and, at least in vitro, have significant expansion capability. The apparently high self-renewal potential makes them strong candidates for delivering genes and restoring organ systems function. However, the high proliferative potential of MSCs, now presumed to be self-renewal, may be more apparent than real. Although expanded MSCs have great proliferation and differentiation potential in vitro, there are limitations with the biology of these cells in vivo. So far, expanded MSCs have failed to induce durable therapeutic effects expected from a true self-renewing stem cell population. The loss of in vivo self-renewal may be due to the extensive expansion of MSCs in existing in vitro expansion systems, suggesting that the original stem cell population and/or properties may no longer exist. Rather, the expanded population may indeed be heterogeneous and represents several generations of different types of mesenchymal cell progeny that have retained a limited proliferation potential and responsiveness for terminal differentiation and maturation along mesenchymal and non-mesenchymal lineages. Novel technology that allows MSCs to maintain their stem cell function in vivo is critical for distinguishing the elusive stem cell from its progenitor cell populations. The ultimate dream is to use MSCs in various forms of cellular therapies, as well as genetic tools that can be used to better understand the mechanisms leading to repair and regeneration of damaged or diseased tissues and organs.

AB - The intriguing biology of stem cells and their vast clinical potential is emerging rapidly for gene therapy. Bone marrow stem cells, including the pluripotent haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and possibly the multipotent adherent progenitor cells (MAPCs), are being considered as potential targets for cell and gene therapy-based approaches against a variety of different diseases. The MSCs from bone marrow are a promising target population as they are capable of differentiating along multiple lineages and, at least in vitro, have significant expansion capability. The apparently high self-renewal potential makes them strong candidates for delivering genes and restoring organ systems function. However, the high proliferative potential of MSCs, now presumed to be self-renewal, may be more apparent than real. Although expanded MSCs have great proliferation and differentiation potential in vitro, there are limitations with the biology of these cells in vivo. So far, expanded MSCs have failed to induce durable therapeutic effects expected from a true self-renewing stem cell population. The loss of in vivo self-renewal may be due to the extensive expansion of MSCs in existing in vitro expansion systems, suggesting that the original stem cell population and/or properties may no longer exist. Rather, the expanded population may indeed be heterogeneous and represents several generations of different types of mesenchymal cell progeny that have retained a limited proliferation potential and responsiveness for terminal differentiation and maturation along mesenchymal and non-mesenchymal lineages. Novel technology that allows MSCs to maintain their stem cell function in vivo is critical for distinguishing the elusive stem cell from its progenitor cell populations. The ultimate dream is to use MSCs in various forms of cellular therapies, as well as genetic tools that can be used to better understand the mechanisms leading to repair and regeneration of damaged or diseased tissues and organs.

KW - Gene Therapy

KW - Mesenchymal stem cells

KW - Vectors

UR - http://www.scopus.com/inward/record.url?scp=28844484109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844484109&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.12.1571

DO - 10.1517/14712598.5.12.1571

M3 - Article

VL - 5

SP - 1571

EP - 1584

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -